Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPY2R | P49146 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875136 | 0.75 | PKM (0.31) | CYP1A2SMN1; SMN2PKM | |
| SCHEMBL13255492 | 0.74 | USP2 (0.37) | CYP1A2TSHRUSP2 | |
| SCHEMBL10053697 | 0.69 | TSHR (0.43) | CYP1A2MEN1KMT2ATSHRGAA | |
| SCHEMBL25875125 | 0.69 | KDM4E (0.34) | HTTALDH1A1NPY2R | |
| SCHEMBL14032700 | 0.67 | USP2 (0.31) | TSHRUSP2 | |
| SCHEMBL25875095 | 0.67 | MEN1 (0.43) | MEN1KMT2ATSHRSMN1; SMN2USP2 | |
| SCHEMBL16902751 | 0.66 | TSHR (0.35) | CYP1A2MEN1KMT2ATSHRHTT | |
| SCHEMBL4440645 | 0.66 | TSHR (0.46) | MEN1KMT2ATSHRSMN1; SMN2HTT | |
| SCHEMBL14077041 | 0.65 | ALDH1A1 (0.36) | SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL25875124 | 0.64 | MEN1 (0.43) | MEN1KMT2ATSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212209-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLR2E, POLI | CYP1A2 4875/4885MEN1 2649/4885KMT2A 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.